V essel wall inflammation and matrix remodeling accompany the development, expansion, and rupture of abdominal aortic aneurysm (AAA). 1,2 Although the causal role of inflammation in the development of AAA can be debated, the association of vessel wall inflammation and matrix remodeling with changes in tensile strength, aortic expansion, and aortic rupture is well documented. 2 The recruitment and proliferation of leukocytes within the aortic wall and release of mediators that promote matrix metalloproteinase (MMP) expression and activation are key determinants of clinical outcome in AAA. 1,2 However, in the current management guidelines, these and other key molecular and cellular processes in the pathogenesis of AAA are neglected, and clinical decisions are made solely based on aneurysm size, expansion rate, and symptoms. 3, 4 As such, the rupture risk associated with small AAAs is not addressed by current guidelines, and the management strategies may impose an unnecessary risk of repair surgery to subjects with large but stable AAA.
MMP-Targeted Imaging of Aneurysm
to evaluate the predictive value of 18 F-FDG positron emission tomographic imaging in AAA showed an inverse relationship between 18 F-FDG uptake and future expansion or rupture in subjects with AAA, 6 highlighting the necessity of more specific tracers for imaging inflammation and remodeling in AAA.
MMPs play a key role in vascular remodeling. 2, 13, 14 Radiolabeled tracers that bind to activated MMPs have shown promise for imaging vascular remodeling by microsingle photon emission computed tomographic (SPECT) imaging. 15, 16 In a previous study, we showed that MMPtargeted imaging can predict arterial expansion in a surgical model of carotid artery aneurysm. 16 In that study, the MMP signal was specific, and it paralleled CD68 expression in the vessel wall. Although promising, the surgical nature of carotid aneurysm, which prevented the unequivocal discrimination of tracer uptake in the vessel wall from uptake in the surrounding surgical wound, and the absence of spontaneous aneurysm rupture, which prevented assessment of the risk of rupture, mandated further evaluation in clinically relevant animal models. As a bridge to future clinical studies, we investigated the feasibility of MMP-targeted imaging for detection of MMP activity and inflammation in a nonsurgical murine model of AAA with potential for spontaneous aortic rupture. Here, we demonstrate the feasibility and effectiveness of MMP imaging in AAA and establish its predictive value for AAA propensity to expansion and rupture.
Methods
Details of Materials and Methods are available in the Data Supplement.
Animal Model
An osmotic minipump (ALZET model 2004) was implanted subcutaneously in 13-to 15-week-old male mice under isoflurane (1%-3%) anesthesia, through which angiotensin II (1000 μg/kg per day; n=66; Table I in the Data Supplement) was administered for up to 28 days. To achieve a broad range of responses, B6.129P2-Apoe tm1Unc /J and C57BL/6J mice from Jackson Laboratories and their offspring were used for this study. Animals infused with normal saline or nothing (n=16) were used as control. Experiments were performed according to the regulations of Yale University and VA Connecticut Healthcare System's Animal Care and Use Committees.
Imaging
The precursor form of RP805, a technetium-99m-labeled tracer with specificity for activated form of MMPs, was radiolabeled as described. 17 Micro-SPECT/CT imaging was performed on a highresolution small animal imaging system (X-SPECT; Gamma Medica-Ideas, Northridge, CA) equipped with 1-mm low-energy pinhole collimators, as described with minor modifications. 15, 16, 18 
Statistical Analysis
All data are presented as mean±SD. The Levene test was used to assess the equality of variances. The statistical significance of the data in multiple groups with equal variances was examined using 1-way ANOVA with Tukey post hoc analysis. If the Levene test indicated that variances were not equal, the Welch ANOVA with the Games-Howell post hoc procedure was used. The Pearson correlation coefficient for linear regression was calculated to test the association between different parameters. The Welch t test was used to compare the tracer uptake at 1 week between those mice that developed AAA or rupture and those without AAA at 4 weeks. The statistical significance was set at P<0.05.
Statistical analysis was performed using GraphPad Prism version 6.03 for Windows or SPSS Statistics for Windows, version 21.0 (for the Levene test and Welch ANOVA).
Results
Of 66 mice infused with angiotensin II for up to 4 weeks, 17 animals (26%) died because of aortic rupture ascertained thorough postmortem examination. In contrast, all saline-infused control mice survived during this period ( Figure 1A ). On ex vivo morphometric analysis at 4 weeks, the maximal external diameter of suprarenal abdominal aorta in the control group was found to be 0.83±0.07 mm. Based on this, the upper limit of normal diameter range was established at the mean±2SD of 0.97 mm. Aortas above this upper limit were considered aneurysmal. With this definition, of those animals in the angiotensin II infusion group that survived without rupture for 4 weeks and for whom the tissue was available, 36 had developed AAA. The maximal external aortic diameters in animals with and without AAA were, respectively, 1.62±0.50 and 0.84±0.10 mm, P<0.0001 (Table; Figure 1B 
In Vivo Imaging of MMP Activation in AAA
To detect and quantify MMP activation in AAA in vivo, a group of mice underwent RP805 (a technetium-99m-labeled tracer that specificity targets MMP activation) 17 micro-SPECT/ CT imaging at 4 weeks after angiotensin II or saline infusion. Although there was no visible focal suprarenal aortic uptake of RP805 in saline-treated mice, in a subset of angiotensin II-infused animals, micro-SPECT images obtained 2 hours after RP805 administration showed considerable tracer uptake in suprarenal abdominal aorta, as located by CT angiography (Figure 2A-2C ). Quantification of the RP805 signal showed significantly higher suprarenal abdominal aorta tracer uptake in angiotensin II-infused mice when compared with salineinfused animals (0.11±0.08 versus 0.04±0.00 counts per voxel per MBq injected dose; P<0.0001; n=33 and 9 for angiotensin II-and saline-infused mice, respectively). Morphometric analysis of aortas harvested after imaging confirmed the presence of AAA in 21 of 33 angiotensin II-infused animals. When stratified based on the presence of AAA, MMP tracer uptake was significantly higher in angiotensin II-infused animals with AAA compared with those without AAA (0.15±0.09 [n=21] versus 0.05±0.02 [n=12] counts per voxel per MBq injected dose; P<0.0001; Figure 2D ). RP805 uptake in AAA was also significantly higher than the uptake in aortas of saline-infused mice (P<0.0001; Figure 2D ).
Ex Vivo Imaging
To validate in vivo imaging results, a subset of animals underwent ex vivo planar imaging after in vivo micro-SPECT/CT imaging. Similar to in vivo data, a focal aortic signal was readily detectable on planar images in animals with AAA ( Figure 3A ). Quantification of tracer uptake in suprarenal aorta showed significantly higher RP805 uptake in angiotensin II-infused animals with AAA when compared with salineinfused animals (0.52±0.45 [n=12] versus 0.05±0.02 [n=7] counts per pixel per MBq injected dose; P=0.01; Figure 3B ). The difference in RP805 uptake between angiotensin-infused animals with and without AAA was at borderline significance (P=0.06). Importantly, there was an excellent correlation between in vivo and ex vivo quantification of aortic RP805 uptake (r=0.89; P<0.0001; Figure 3C ). 
Tissue Characterization
The changes in aortic wall composition associated with AAA development were investigated by immunostaining and quantitative reverse transcription polymerase chain reaction. As expected, in both control and angiotensin II-infused animals, aortic lumen was surrounded by a layer of CD31-positive endothelial cells, and the media consisted mostly of α-actinpositive vascular smooth muscle cells. In addition, several CD31-and, in some cases, smooth muscle α-actin-positive small blood vessels were present in the adventitia of aneurysmal aortic segments. Compared with aortas of control animals, a prominent CD68 (macrophage marker)-positive inflammatory infiltrate was present in AAA ( Figure 4A ). This was confirmed by quantitative reverse transcription polymerase chain reaction, which showed significantly higher GAPDHnormalized CD68 expression in AAA relative to control aortas (P<0.05; n=4-13 in each group; Figure 4B ). Similarly, the development of AAA was associated with upregulation of several members of MMP family, including MMP-2, -9, and -12 as detected by quantitative reverse transcription polymerase chain reaction (P<0.05; n=4-13 in each group; Figure 4C ). Finally, MMP activation assessed by zymography was significantly higher in AAA compared with saline-infused control aortas (P<0.05; n=4-12 in each group; Figure 4D ).
Correlates of MMP Activation in AAA
To address the correlates of RP805 uptake in vivo, aortic tissue was frozen immediately after micro-SPECT/CT imaging in a subset of animals (n=15). Comparing micro-SPECT-derived MMP activity in abdominal aorta with aortic MMP activity assessed by zymography, it was found that there was a significant and robust correlation between the 2 measures of MMP activity (r=0.83; P<0.001; Figure 5A ). We also found a significant and robust correlation between micro-SPECT-derived MMP activity and CD68 expression (r=0.89; P<0.0001; Figure 5B ). The correlation between RP805 uptake and zymography or CD68 expression persisted when only animals with AAA were analyzed (r=0.79; P=0.01 or r=0.91; P<0.01, respectively, for zymography and CD68 expression; Figure IIA and IIB in the Data Supplement). Next we investigated whether aortic size is a determinant of RP805 uptake. Combining both saline-infused and angiotensin II-infused animals, it was found that there was a modest, yet significant, correlation between RP805 uptake and aortic diameter (r=0.47; P<0.01; Figure 5C ). However, in animals with AAA, there was no correlation between RP805 uptake and aortic diameter ( Figure IIC in the Data Supplement), indicating that unlike MMP activity or CD68 expression, aortic diameter is not a determinant of RP805 uptake in AAA. Finally, there was a significant correlation between MMP activity quantified by zymography and CD68 expression (r=0.74; P<0.0001; Figure 5D ).
Predictive Value of RP805 Imaging
Next we sought to investigate whether early MMP-targeted imaging can predict ultimate outcome in AAA. A group of mice (n=24) underwent RP805 micro-SPECT imaging at 1 week after the initiation of angiotensin II infusion. These animals were allowed to recover from anesthesia and were followed up for 3 weeks after imaging. Similar to animals imaged at 4 weeks, the RP805 signal was readily detectable in suprarenal aorta of a subset of animals imaged at 1 week ( Figure 6 ). During the follow-up observation period, as expected, a subset of these mice (n=3) died of AAA rupture. Of the surviving animals, 12 had and 9 did not have AAA on ex vivo morphometric analysis at 4 weeks. On retrospective analysis of images, mean tracer uptake in suprarenal abdominal aorta at 1 week in all angiotensin II-infused mice was 0.08±0.05 counts per voxel per MBq injected dose. RP805 at 1 week was significantly higher in animals which died of rupture or developed AAA than those who survived for 4 weeks without AAA (0.10±0.05 versus 0.03±0.02 counts per voxel per MBq injected dose; P<0.0001; Figure 6 ). Similarly, when analyzed as a continuous variable, there was a significant correlation between RP805 uptake at 1 week and aortic diameter at 4 weeks (r=0.53; P<0.01), indicating that early MMP-targeted imaging can predict the outcome in this model of AAA ( Figure 6 ).
Discussion
To our knowledge, this is the first study to evaluate MMPtargeted micro-SPECT/CT imaging for predicting outcome in AAA. In an animal model of AAA with potential for spontaneous rupture, we demonstrate that RP805 uptake in abdominal aorta correlates well with vessel wall MMP activity and .05 (vs saline-infused), n=8, 4, and 13, respectively, for saline-infused, no AAA, and AAA. C, Quantitative RT-PCR assessment of matrix metalloproteinase (MMP)-2, -9, and -12 expression in abdominal aorta of saline infused control mice and angiotensin II-infused mice with AAA or without AAA (no AAA). †P<0.05 for MMP-2 and MMP-12 and P<0.01 for MMP-9 (vs saline-infused animals), *P<0.05 (vs no AAA). For MMP-2: n=6, 4, and 11, for MMP-9: n=7, 4, and 12; and for MMP-12: n=7, 4, and 12, respectively, for saline-infused, no AAA, and AAA. D, Zymographic quantification of MMP activity in abdominal aorta of saline infused control mice and angiotensin II-infused mice with AAA or without AAA (no AAA). †P<0.05 (vs saline-infused animals), n=7, 4, and 9, respectively, for saline-infused, no AAA, and AAA. AU indicates arbitrary unit. MMP-Targeted Imaging of Aneurysm macrophage content. Importantly, we show that early SPECT imaging shows promise regarding the animals' propensity for future aortic expansion or death from aneurysm rupture as a composite end point.
In the United States, AAA is responsible for ≈10 000 deaths per year, mostly because of rupture. 19 Clinically, AAA is often asymptomatic, and the main goal of treatment is to avoid the development of morbid complications. This can be achieved through preventive measures, including surgical or endovascular aneurysm repair in those subjects who are at high risk of rupture. According to current management guidelines, AAA rupture risk is determined based on its size, retrospective expansion rate, or presence of symptoms. Thus, subjects with small asymptomatic AAA are managed conservatively using a watch-and-wait-strategy focused on treating risk factors and tracking aneurysm expansion. 3 However, a notable number of aneurysm ruptures occurs during this period in small AAA, which do not meet the criteria for invasive treatment. 20 This calls for refining AAA risk stratification criteria based on stateof-the-art diagnostic tools and underlying pathobiology. 21 Molecular imaging techniques can be used to detect and quantify the abundance and activity of key molecular and cellular players in AAA development and rupture. Through the release of proinflammatory chemokines and cytokines and of proteases, such as MMPs, inflammatory cells contribute to aneurysm expansion and rupture, 22 and thus, they could be suitable targets for molecular imaging of AAA. 21 Indeed, it is shown that AAA expansion in humans is associated with a high density of inflammatory cells in the adventitia. 23 The most advanced molecular imaging techniques for detection of vascular inflammation and phagocytic activity that have been used in both preclinical and clinical settings are 18 F-FDG positron emission tomography and iron oxide nanoparticle-based MRI. 7,24-26 18 F-FDGe is not specific for inflammatory cells as it can be retained in any highly metabolizing cell, and 18 F-FDG positron emission tomography has shown contradicting results in predicting aortic aneurysm rupture. 6, 9 Ultrasmall particles of iron oxide-based MRI has shown encouraging results in predicting AAA growth. 26 However, many issues remain to be addressed about the use of this approach, including interference from endogenous iron present because of hemorrhage or thrombus, the modest degree of signal loss, uncertainties about the quantification methodology, nonspecificity for macrophages, for example, because of entrapment within thrombus, and nontargeted nature of ultrasmall superparamagnetic iron oxide contrast agent particles. 21, 27 Given the role of MMPs in the pathogenesis of aneurysm, MMP-targeted imaging is an alternative approach for detection of vascular inflammation and remodeling in aortic aneurysm. Indeed, several members of MMP family are upregulated in ruptured human AAA, and plasma levels of others are found to be elevated. 13, 14 As such, MMPs seem to be suitable targets for molecular imaging of aneurysms to predict expansion and rupture. The MMP family of zinc-dependent endopeptidases consists of ≈25 related proteins that are synthesized as proenzymes. 28 The activation of MMP proenzymes (whether allosteric or proteolytic) exposes the catalytic domain targeted by technetium-99m-RP805 and its 111 In-labeled homologue RP782, which has been used to detect MMP activation in murine aneurysm. 16 Other MMPtargeted probes, including an activatable fluorescent imaging agent, MMPsense 680, and a gadolinium-based MRI contrast agent, P947, have been evaluated for imaging aneurysm in murine models. [29] [30] [31] However, unlike MMP-specific radiotracers, it is not clear whether there is any potential path to application of these agents for noninvasive imaging in humans. 21 The murine model of AAA used in this study offers several advantages compared with other rodent models of AAA. In addition to the potential for spontaneous rupture, the angiotensin II-induced model of AAA recapitulates many aspects of human disease, including macrophage infiltration and MMP activation, 32, 33 increasing the likelihood that the data obtained with this model are relevant to human AAA. Combining 2 strains of mice and their offspring that show different rates of aneurysm induction in our study 34 might have further increased this likelihood. The absence of a surgical wound nearby, which can interfere with image analysis, as encountered in surgical models of AAA, is another practical advantage of angiotensin II-induced murine AAA. Indeed, target gene expression in the surrounding wound was a confounding factor in a previous study on imaging carotid aneurysm. 16 Although we have addressed the MMP-specificity of tracer uptake in aneurysm using an excess unlabeled precursor, 16 the potential contribution of surgical wound and damage to perivascular tissue to tracer uptake in vivo remained a concern. Despite the absence of perivascular uptake of the tracer in our model, the small size of aorta in the mouse can be a challenge to in vivo quantification of tracer uptake. To address this concern, we validated in vivo micro-SPECT-derived quantitative measures of RP805 uptake using the data derived from ex vivo planar images of the corresponding segments of abdominal aorta, demonstrating an excellent correlation between in vivo and ex vivo measurements of tracer uptake.
Various groups of investigators have used different criteria to define AAA in the mouse. [35] [36] [37] Here, to ascertain the validity of our results, we used a rather stringent threshold based on mean+2SD of aortic diameter in control mice to define AAA. We found the MMP signal to be significantly higher in AAA than in abdominal aorta of saline-treated control mice or those angiotensin II-infused animals that had not developed aneurysm. As expected, CD68 (macrophage marker) and several members of MMP family were found to be upregulated in AAA in our model. MMP enzymatic activity in vivo is dependent on MMP (and tissue inhibitors of MMPs) expression, as well as MMP activation, a process that exposes the catalytic domain that is the target of RP805. Consistent with its high affinity and specificity for MMP activation, RP805 uptake in vivo closely paralleled aortic MMP activity assessed by zymography ex vivo. The strong correlation between MMP activity and CD68 expression in this study is in accordance with the understanding of the pathobiology of the disease where inflammation and matrix remodeling are 2 closely related processes. This association was also reflected in the robust correlation between the RP805 signal in vivo and CD68 expression. This indicates a potential role of RP805 imaging not only in depicting MMP activation but also in assessing inflammation within the vessel wall. Given the current lack of a reliable, specific imaging technique for assessment of inflammation, the potential of MMP imaging in depicting vessel wall inflammation is of interest to investigators, and possibly in the future, clinicians for characterization of inflammatory vascular diseases. To establish a direct link between RP805 uptake and inflammation in aneurysm, future studies should explore the effects of anti-inflammatory interventions on RP805 uptake in AAA.
There is considerable heterogeneity in response to angiotensin II infusion, as some animals do not develop aneurysm and others develop a large aneurysm or die of rupture. Therefore, we opted not to exclude any animal as outlier. The absence of a correlation between AAA diameter (the conventional clinical risk stratifying criterion) and RP805 uptake excludes the possibility that the tissue mass is the major determinant of tracer uptake in AAA. In conjunction with the robust correlation between MMP activity or CD68 expression and MMP tracer uptake in aneurysmal aorta, this lack of correlation with AAA size suggests that RP805 imaging offers the opportunity to measure the underlying pathobiological processes in AAA that are not necessarily reflected in aneurysm size. RP805 micro-SPECT imaging at 1 week after initiation of angiotensin II infusion demonstrated that MMP imaging is useful for identifying those aneurysms that will expand or rupture. Indeed, on these early images, the abdominal aorta signal in those mice that ended up developing AAA or die of aneurysm rupture in the following weeks was significantly higher than in those mice that did not develop AAA. Because of limitations of CT imaging, we could not address the potential presence of small AAAs at the time of early imaging. However, we did detect 3 AAAs on CT images obtained at 1 week, and even after excluding the data from these mice, the difference in RP805 uptake between those mice with rupture or AAA and those with no AAA at 4 weeks remained statistically significant (data not shown). In practical terms, any potential future application of MMP-targeted molecular imaging for prediction of expansion or rupture will be limited to those patients with existing AAA.
In conclusion, MMP-targeted molecular imaging can detect MMP activation and vessel wall inflammation in vivo in AAA and help assess a murine AAA's propensity for expansion and rupture. Whether the extent and magnitude of inflammation and MMP activation seen in the experimental mouse model correspond exactly with what is seen in human AAA remains to be determined. Ultimately, although the study demonstrates proof of concept in the experimental setting, human studies are necessary to demonstrate the feasibility of MMP-directed imaging for predicting accelerated progression of AAA and also risk of rupture. Clinical translation of MMP imaging can lead to better risk stratification of patients with small AAA to identify the subset that would benefit from for more invasive treatment or more frequent surveillance. It can also help spare those patients with large, but stable AAA from the unnecessary risk associated with invasive aneurysm repair. Finally, beyond its potential role in AAA characterization, MMPtargeted imaging can potentially help the development and monitoring of the effects of emerging medical therapies for AAA and other vascular diseases. 38
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